$SRDX formed a Bullish Double Bottom pattern on a 1 Year Chart.

🔍 Scan more patterns globally:

👉 doughcook.com

#srdx #Bullish #technicalanalysis #stockpatterns #doughcook

-Note the Above reply was Reply part 12 of ? of the thread about Space Rocks Deluxe's Development. And I won't be breaking the Reply part chain of Reply's since it will continue after this Note Reply in the future when I have more to share with you Followers and Non Followers about #SRDX

Surmodics turns positive with Nasdaq delisting notice for GTCR deal (SRDX:NASDAQ) Please provide the article or its main content so I can generate an SEO-friendly meta description for you.

Surmodics turns positive with Nasdaq delisting notice for GTCR deal

#srdx

Origin | Interest | Match

Just In: ( NASDAQ: #SRDX ) Surmodics Inc. (NASDAQ: SRDX) Climbs to New 52-Week High

BREAKING NEWS: ( NASDAQ: #SRDX ) Surmodics Announces FTC Does Not Intend to Appeal Denial of Injunction, Order Preventing Closing Set to Expire Today

Surmodics Announces FTC Does Not Intend to Appeal Denial of Injunction, Order Preventing Closing Set to Expire Today Surmodics (Nasdaq: SRDX) announced it expects to close its previously announced acquisition by an affiliate of GTCR promptly after the Federal Trade Commission and certain state regulators said they do not intend to appeal the District Court's November 10, 2025 denial of a preliminary injunction.Consummation remains subject to a Temporary Restraining Order that prevents closing before 5:00 p.m. Central Time on November 17, 2025, and to satisfaction or waiver of merger agreement closing conditions, including absence of an injunction and absence of a Company Material Adverse Effect.

#SRDX Surmodics Announces FTC Does Not Intend to Appeal Denial of Injunction, Order Preventing Closing Set to Expire Today

www.stocktitan.net/news/SRDX/surmodics-anno...

Surmodics Announces U.S. District Court Denies Request for Preliminary Injunction to Block Proposed Acquisition by GTCR Surmodics, Inc., a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that the United States District Court for the Northern District of Illinois has denied a request by the U.S. Federal Trade Commission and certain state regulators to issue a preliminary injunction that would have prevented...

#SRDX Surmodics Announces U.S. District Court Denies Request for Preliminary Injunction to Block Proposed Acquisition by GTCR

www.stocktitan.net/news/SRDX/surmodics-anno...

Surmodics Announces Outcomes from 160 Patients in PROWL Registry Evaluating Pounce™ Thrombectomy Platform in Treatment of Real-World Limb Ischemia Presentations Surmodics (Nasdaq: SRDX) reported outcomes from 160 real-world patients in the PROWL registry evaluating the Pounce™ Thrombectomy Platform for infrainguinal limb ischemia; results were presented November 3, 2025.Key metrics: procedural success 91.7%, device-related major adverse events 0.6%, core-lab TIPI 2-3 flow 94.8%, technical success 83.2%, average device use 24.1 minutes, median 2 passes. 43.1% presented with symptoms >2 weeks; 78.8% required no adjunctive clot therapies. 30-day all-cause outcomes included major amputation 8.1%, target lesion revascularization 7.5%, and death 4.4%.

#SRDX Surmodics Announces Outcomes from 160 Patients in PROWL Registry Evaluating Pounce™ Thrombectomy Platform in Treatment of Real-World Limb Ischemia Presentations

www.stocktitan.net/news/SRDX/surmodics-anno...

Surmodics Announces PROWL Registry 160-Patient Data to be Presented in Industry-Sponsored Session at VIVA Conference on November 3 Surmodics (Nasdaq: SRDX) announced that updated safety and performance data from the PROWL registry — covering 160 patients with symptomatic lower-extremity (infrainguinal) thromboembolic disease treated with the Pounce™ Thrombectomy Platform — will be presented in an industry-sponsored session at the 23rd Annual VIVA Conference.Presenters Dr. Sean Lyden, Dr. Joseph Campbell, and Dr. Peter Monteleone will present case insights and real-world clinical outcomes on November 3, 2025 at 3:15 PM PST at Wynn Las Vegas, InnoSphere.

#SRDX Surmodics Announces PROWL Registry 160-Patient Data to be Presented in Industry-Sponsored Session at VIVA Conference on November 3

www.stocktitan.net/news/SRDX/surmodics-anno...

Surmodics Announces Results from Sex-Specific Analysis of the PROWL Registry Study of Real-World Limb Ischemia Patients Treated with the Pounce™ Thrombectomy Platform Surmodics (Nasdaq: SRDX) presented a sex-specific analysis of 160 real-world infrainguinal patients from the PROWL registry treated with the Pounce Thrombectomy Platform.Key results through 30 days: procedural (patient-level) success 94.7% in women vs 89.9% in men (p=0.3765); technical (lesion-level) success 91.4% in women vs 78.3% in men (p=0.0261); core-lab adjudicated thrombus removal complete/substantial ~93.8% women vs 94.3% men; arterial flow (TIPI Grade 2/3) improved in 97.2% women vs 93.4% men. Composite freedom from all-cause MAEs was 73.3% women vs 86.0% men (p=0.0599). The registry includes acute, subacute, and chronic presentations, with ~42–44% presenting >2 weeks of symptoms.

#SRDX Surmodics Announces Results from Sex-Specific Analysis of the PROWL Registry Study of Real-World Limb Ischemia Patients Treated with the Pounce™ Thrombectomy Platform

www.stocktitan.net/news/SRDX/surmodics-anno...

Surmodics Announces PROWL Registry Sex-Specific Data to be Presented at TCT Conference on October 28 Surmodics (Nasdaq: SRDX) will present sex-specific results from the PROWL registry evaluating the Pounce™ Thrombectomy Platform for non-surgical removal of emboli and thrombi in peripheral arterial vasculature.The analysis includes 160 patients with symptomatic infrainguinal (lower extremity) vessels. Presentation by Dr. Peter Monteleone is scheduled for October 28, 2025 at 12:40 PM PDT during the 37th Annual TCT Symposium at Moscone Center, Station 3, Halls B-C in San Francisco.

#SRDX Surmodics Announces PROWL Registry Sex-Specific Data to be Presented at TCT Conference on October 28

www.stocktitan.net/news/SRDX/surmodics-anno...

Surmodics Reports Third Quarter of Fiscal Year 2025 Financial Results; Updates Fiscal Year 2025 Financial Guidance Surmodics (Nasdaq: SRDX) reported Q3 fiscal 2025 results with total revenue of $29.6 million, down 3% year-over-year. The company experienced a GAAP net loss of $(5.3) million, an improvement from $(7.6) million in the prior year period, while Adjusted EBITDA increased to $3.4 million from $1.6 million.Key highlights include the commercial release of the Pounce XL Thrombectomy System and publication of the TRANSCEND clinical trial demonstrating SurVeil™ DCB's non-inferiority. The company updated its FY2025 guidance, now expecting revenue between $116.5-$118.5 million. The pending acquisition by GTCR continues to face FTC challenges.Medical Device segment revenue decreased 5% to $22.2 million, while In Vitro Diagnostics revenue grew 6% to $7.4 million. The company maintained a strong balance sheet with $32.7 million in cash and investments.

#SRDX Surmodics Reports Third Quarter of Fiscal Year 2025 Financial Results; Updates Fiscal Year 2025 Financial Guidance

www.stocktitan.net/news/SRDX/surmodics-repo...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with improving money flow, Thu Jun 5th - #TBCH #SRDX #RIGL #OCUL #NATR #ENTA #DRIO #CRBP #BWMN #AEHL #WGO #SQNS #ORN #GHM #DBD #CPF #BV - More: crystalequityresearch.com/SmCpStr/ - #smallcap

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with bullish moving average convergence divergence crossovers, Wed May 14th - #UNIT #TLS #SRDX #PAL #OMCL #LUCD #KGEI #GURE #ENSC #CLNN #BLUE #AUDC #VOC #UTZ #NCDL #KODK #CIA #ARIS - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Surmodics Reports Q2 Loss, Revenue Drop, and FTC Roadblock in GTCR Takeover Battle Medical device maker faces 12% revenue decline and FTC merger challenge. New Pounce XL launch shows promise amid headwinds. See full earnings analysis.

#SRDX Surmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial Guidance

www.stocktitan.net/news/SRDX/surmodics-repo...

Revolutionary Blood Clot Treatment: Pounce XL Shows 80% Success Rate in Just 20 Minutes Advanced thrombectomy system treats larger vessels without additional equipment. Clinical data shows 80% success rate in first-pass clot removal with minimal complications.

#SRDX Surmodics Announces Commercial Release of Pounce™ XL Thrombectomy System, Enabling Rapid Non-Surgical Clot Removal in Iliac and Femoral Arteries

www.stocktitan.net/news/SRDX/surmodics-anno...

Revolutionary Blood Clot Treatment: Surmodics' New Pounce XL System Tackles Larger Arteries Surmodics expands thrombectomy portfolio with FDA-cleared Pounce XL system for larger peripheral arteries, demonstrating successful first clinical use in 8mm vessel restoration.

#SRDX Surmodics Announces Successful Early Clinical Use of Pounce™ XL Thrombectomy System, Suitable for Non-Surgical Removal of Thrombi and Emboli from Iliac and Femoral Arteries

www.stocktitan.net/news/SRDX/surmodics-anno...

Surmodics' $627M Merger in Focus as New FDA Approval Offsets Revenue Decline Surmodics posts $29.9M revenue, wider loss of $3.7M in Q1. Bright spots include FDA clearance for Pounce XL system and positive PROWL study data amid pending GTCR acquisition.

#SRDX Surmodics Reports First Quarter of Fiscal Year 2025 Financial Results

www.stocktitan.net/news/SRDX/surmodics-repo...